GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California. Show more

Location: 1525 O’Brien Drive, Menlo Park, CA, 94025, United States | Website: https://grail.com | Industry: Diagnostics & Research | Sector: Healthcare


Market Cap

3.222B

52 Wk Range

$12.76 - $103.00

Previous Close

$89.39

Open

$91.68

Volume

797,917

Day Range

$83.26 - $91.68

Enterprise Value

1.793B

Cash

602.8M

Avg Qtr Burn

-92.51M

Insider Ownership

14.00%

Institutional Own.

68.56%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date